Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.

Conduit Pharmaceuticals Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of May 2, 2024. The company's filing, identified by accession number 0001493152-24-017464 and submission type POS AM, has been acknowledged by the SEC, marking a pivotal step in Conduit Pharmaceuticals' regulatory journey. The effectiveness of this submission is a key development for the company, which is listed under the CIK number 0001896212 and file number 333-275056.